Literature DB >> 19415719

Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.

Chul Jang Kim1, Kayoko Nishi, Takahiro Isono, Yusuke Okuyama, Yukihiro Tambe, Yusaku Okada, Hirokazu Inoue.   

Abstract

Alternative splicing in the cyclin D1 gene produces cyclin D1b variant which lacks a C-terminal region containing the threonine-286 (T286) phosphorylation site required for nuclear export. We have shown that the expression of the cyclin D1b variant is detected in about 60% of human bladder cancer tissues (15/26) and cell lines (3/5). To examine the role of the cyclin D1b variant in bladder carcinogenesis, we introduced wild-type cyclin D1a, cyclin D1b variant or mutant cyclin D1-T286A cDNAs into a human bladder cancer cell line, SBT991, in which cyclin D1b transcript was not expressed, and compared their oncogenic activities. Ectopic expression of cyclin D1b promoted cell invasiveness and anchorage-independent growth of the cancer cells. On the other hand, cyclin D1-T286A enhanced anchorage-independent growth, but did not promote cell invasiveness. The amount of nuclear-localized cyclin D1b and cyclin D1-T286A was higher than that of nuclear-localized cyclin D1a. In addition, introduction of siRNA specific for cyclin D1b into cells of the T24 bladder cancer cell line, in which cyclin D1b transcript was expressed, significantly suppressed cell invasiveness. Immunoprecipitation analysis revealed that cyclin D1a and cyclin D1-T286A could bind to cyclin-dependent kinase 4 (CDK4) but cyclin D1b has lost its capacity to associate with CDK4. Unlike cyclin D1a and cyclin D1-T286A, expression of cyclin D1b did not enhance phosphorylation of Rb protein in SBT991 cells. These results indicate that cyclin D1b promotes cell invasiveness independent of binding to CDK4 to enhance Rb phosphorylation. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415719     DOI: 10.1002/mc.20547

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  14 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

2.  Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Authors:  Maria Paola Paronetto; Manuela Cappellari; Roberta Busà; Simona Pedrotti; Roberta Vitali; Clay Comstock; Terry Hyslop; Karen E Knudsen; Claudio Sette
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 3.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

4.  Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo.

Authors:  Ning Wang; Heng Wei; Duo Yin; Yanming Lu; Yao Zhang; Di Jiang; Yan Jiang; Shulan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity.

Authors:  Chul Jang Kim; Yukihiro Tambe; Ken-Ichi Mukaisho; Hiroyuki Sugihara; Akihiro Kawauchi; Hirokazu Inoue
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

6.  Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

Authors:  Nicholas A Olshavsky; Clay E S Comstock; Matthew J Schiewer; Michael A Augello; Terry Hyslop; Claudio Sette; Jinsong Zhang; Linda M Parysek; Karen E Knudsen
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

7.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.

Authors:  Pradeep Kumar Kopparapu; Stephen A Boorjian; Brian D Robinson; Martin Downes; Lorraine J Gudas; Nigel P Mongan; Jenny L Persson
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

8.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

Review 9.  AR function in promoting metastatic prostate cancer.

Authors:  Michael A Augello; Robert B Den; Karen E Knudsen
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 10.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.